Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Key Inclusion Criteria: * Male and female patients 18 years to 70 years of age (inclusive) * Body weight at least 35 kg and not more than 120 kg and must have a body mass index (BMI) within the range of 18 - 35 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2 at screening * Diagnosed with SjD and/or SLE as determined by the investigator * Have active disease (SjD and/or SLE) that may benefit from B-cell depletion therapy, as determined by the investigator. * Participants currently receiving protocol-allowed SoC should be on stable doses of SoC medications for 4 weeks prior to first dosing of study treatment Key Exclusion Criteria: * Use of prohibited therapies * Active viral, bacterial or other infections requiring systemic treatment at the time of screening or baseline or history of recurrent clinically significant infection * Receipt of live/attenuated vaccine within a 4-week period before first dosing * Uncontrolled co-existing serious disease * Pregnant or nursing (lactating) women * Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, refusing or unable to use highly effective methods of contraception while on study treatment and for 6 months after stopping of study drug Other protocol-defined inclusion/exclusion criteria may apply.